Roth E - Search Results

1

Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.

Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, Hamlin C, Perevozskaya I, Davies MJ, Kush D, Mitchel YB; Ezetimibe/Simvastatin + Fenofibrate Study Group. Farnier M, et al. Among authors: roth e. Am Heart J. 2007 Feb;153(2):335.e1-8. doi: 10.1016/j.ahj.2006.10.031. Am Heart J. 2007. PMID: 17239698 Clinical Trial.

2

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.

Robinson JG, Farnier M, Kastelein JJP, Roth EM, Taskinen MR, Colhoun HM, Brunet A, DiCioccio AT, Lecorps G, Pordy R, Baccara-Dinet MT, Cannon CP. Robinson JG, et al. J Clin Lipidol. 2019 Nov-Dec;13(6):979-988.e10. doi: 10.1016/j.jacl.2019.10.004. Epub 2019 Oct 14. J Clin Lipidol. 2019. PMID: 31708410 Free article. Clinical Trial.

3

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.

Roth EM, Kastelein JJP, Cannon CP, Farnier M, McKenney JM, DiCioccio AT, Brunet A, Manvelian G, Sasiela WJ, Baccara-Dinet MT, Zhao J, Robinson JG. Roth EM, et al. J Clin Lipidol. 2020 Sep-Oct;14(5):707-719. doi: 10.1016/j.jacl.2020.07.009. Epub 2020 Jul 25. J Clin Lipidol. 2020. PMID: 32928709 Free article. Clinical Trial.

4

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS; PROFICIO Investigators. Stein EA, et al. Eur Heart J. 2014 Sep 1;35(33):2249-59. doi: 10.1093/eurheartj/ehu085. Epub 2014 Mar 4. Eur Heart J. 2014. PMID: 24598985

5

Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.

Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH. Roth EM, et al. Am J Cardiovasc Drugs. 2010;10(3):175-86. doi: 10.2165/11533430-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20524719 Clinical Trial.

6

Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.

Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA. Roth EM, et al. Cardiovasc Drugs Ther. 2010 Dec;24(5-6):421-8. doi: 10.1007/s10557-010-6266-4. Cardiovasc Drugs Ther. 2010. PMID: 20953684 Clinical Trial.

7

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.

Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. Roth EM, et al. Int J Cardiol. 2014 Sep;176(1):55-61. doi: 10.1016/j.ijcard.2014.06.049. Epub 2014 Jul 2. Int J Cardiol. 2014. PMID: 25037695 Free article. Clinical Trial.

8

A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).

Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH. Maki KC, et al. Clin Ther. 2013 Sep;35(9):1400-11.e1-3. doi: 10.1016/j.clinthera.2013.07.420. Epub 2013 Aug 30. Clin Ther. 2013. PMID: 23998969 Clinical Trial.

9

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.

Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG. Stein EA, et al. Eur Heart J. 2010 Feb;31(4):480-8. doi: 10.1093/eurheartj/ehp601. Epub 2010 Jan 22. Eur Heart J. 2010. PMID: 20097702 Free PMC article. Clinical Trial.

10

Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.

Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA. Roth EM, et al. J Cardiovasc Pharmacol. 2009 Sep;54(3):196-203. doi: 10.1097/FJC.0b013e3181b0cf71. J Cardiovasc Pharmacol. 2009. PMID: 19597368 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,432 results

Search Page